Octreotide

證據等級: L5

預測適應症: 2 個

---

目錄

1. Octreotide
2. Octreotide: From Neuroendocrine Tumours to Vulvar Inverted Follicular Keratosis
   1. One-Sentence Summary
   2. Quick Overview
   3. Why is This Prediction Reasonable?
   4. Clinical Trial Evidence
   5. Literature Evidence
   6. New Zealand Market Information
   7. Safety Considerations
   8. Conclusion and Next Steps
   9. Disclaimer

---

## 藥師評估報告

Octreotide: From Neuroendocrine Tumours to Vulvar Inverted Follicular Keratosis

One-Sentence Summary

Octreotide is a somatostatin analog originally used for acromegaly, carcinoid syndrome, neuroendocrine tumours, and secretory diarrhea. The TxGNN model predicts it may be effective for Vulvar Inverted Follicular Keratosis, but this prediction is currently supported by zero clinical trials and zero publications — it rests solely on a computational score.

Quick Overview

Item	Content
Original Indication	Acromegaly, carcinoid syndrome, neuroendocrine tumours (e.g. VIPoma), secretory diarrhea
Predicted New Indication	Vulvar Inverted Follicular Keratosis
TxGNN Prediction Score	99.58% (rank 4035)
Evidence Level	L5
New Zealand Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Octreotide is a somatostatin analog that acts via SSTR2/SSTR5 receptors to suppress neuroendocrine secretion (growth hormone, insulin, glucagon, and gastro-entero-pancreatic hormones) and, in some cases, inhibit neuroendocrine tumour proliferation. Its established clinical use is concentrated in acromegaly, carcinoid syndrome, neuroendocrine tumours, and secretory diarrhea.

Vulvar inverted follicular keratosis is a benign follicular epithelial proliferation driven by keratinocyte hyperkeratosis, with no known link to somatostatin receptor signaling. There is currently no mechanistic, preclinical, or clinical literature connecting SSTR2/SSTR5 pathway modulation to this lesion type.

Given the complete absence of original MOA documentation (data gap) and the lack of any supporting trials or literature, this prediction should be regarded as a pure computational output of the TxGNN model rather than a mechanistically grounded hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

New Zealand Market Information

Octreotide is not currently marketed in New Zealand, and no authorizations are on record (0 licenses).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

• Evidence level is L5 (model prediction only) — no clinical trials, literature, or case reports link octreotide to vulvar inverted follicular keratosis, and the proposed mechanism (SSTR2/SSTR5 signaling) has no established connection to this benign keratotic lesion.
• A blocking data gap exists for TFDA/Medsafe package insert warnings and contraindications, which prevents this candidate from entering the S1 safety pre-assessment stage.

To proceed, the following is needed:

• TFDA/Medsafe package insert data (warnings, contraindications) to clear the blocking safety data gap
• Formal mechanism of action (MOA) documentation from DrugBank or equivalent source
• Preclinical or mechanistic studies evaluating somatostatin receptor expression in follicular/keratotic skin lesions
• Any case reports or off-label use data, if they exist, to establish a minimal evidence base before further evaluation

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---